Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 34.21% | -56.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.21% | -56.41% | |||
| Cost of Revenue | 13.04% | 12.12% | |||
| Gross Profit | 57.14% | -73.77% | |||
| SG&A Expenses | -15.49% | 3.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.68% | 6.65% | |||
| Operating Income | 151.75% | -122.91% | |||
| Income Before Tax | 132.66% | -127.11% | |||
| Income Tax Expenses | 58.47% | -48.01% | |||
| Earnings from Continuing Operations | 131.65% | -127.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 131.65% | -127.33% | |||
| EBIT | 151.75% | -122.91% | |||
| EBITDA | 152.66% | -122.73% | |||
| EPS Basic | 131.39% | -127.28% | |||
| Normalized Basic EPS | 132.39% | -127.05% | |||
| EPS Diluted | 129.90% | -129.26% | |||
| Normalized Diluted EPS | 131.49% | -127.83% | |||
| Average Basic Shares Outstanding | 0.81% | 0.19% | |||
| Average Diluted Shares Outstanding | 3.76% | -2.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||